Hodgkin Lymphoma

The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared promising for adults with bulky stage II or stage III/stage IV classic Hodgkin lymphoma, according to study results.

NEW ORLEANS — The addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma, according to study results.

The FDA approved brentuximab vedotin in combination with chemotherapy for treatment of certain children with Hodgkin lymphoma, according to the agent’s manufacturer.

The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard treatment among pediatric patients with high-risk Hodgkin lymphoma, according to study results.

Patients with early-stage classic Hodgkin lymphoma and other neoplasms exhibited higher risk for cardiovascular disease-associated mortality compared with cancer-associated mortality later in life, according to study results.

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.

Men, older patients and patients with low income were among those with elevated risk for CVD hospitalization prior to receiving a diagnosis of potentially curable cancer, researchers reported.

CHICAGO — Combining brentuximab vedotin with a chemotherapy regimen as first-line therapy conferred an objective response in 88% of younger patients with newly diagnosed advanced-stage classical Hodgkin lymphoma, study results show.

CHICAGO — The addition of brentuximab vedotin to frontline chemotherapy significantly extended OS among patients with advanced classical Hodgkin lymphoma, according to study results presented at ASCO Annual Meeting.

Natural killer cells combined with a bispecific antibody induced response among nearly 90% of patients with relapsed or refractory CD30-positive lymphoma, according to phase 1/phase 2 trial results.